Reference: Livingston, E. H., Malani, P. N., & Creech, C. B. (2021). The Johnson & Johnson vaccine for COVID-19. JAMA Patient Page. https://doi.org/10.1001/jama.2021.2927 Summary: The Johnson & Johnson COVID-19 vaccine employs a unique approach using a modified adenovirus to induce an immune response without causing infection. Unlike mRNA vaccines from Pfizer and Moderna, which require […]
Reference: VigiAccess. (2021). VigiAccess™. Retrieved from https://who-umc.org Summary: VigiAccess provides a comprehensive overview of adverse drug reactions (ADRs) associated with Covid-19 vaccines, highlighting a total of 2,183,912 reports. The data illustrates the geographical distribution of ADRs, with significant counts reported across continents such as the Americas, Europe, and Asia. The analysis categorises ADRs into various
Reference: The NewERA. (2021, April 8). SAHPRA destroyed in court – Ivermectin available. Summary: On 8 April 2021, a significant court ruling declared that the South African Health Products Regulatory Authority (SAHPRA) could no longer restrict access to Ivermectin, a treatment believed to help with HIV and COVID-19. The High Court found SAHPRA’s actions to
Reference: Taniokal, H., Taniokal, S., & Kaga, K. (2021). Why COVID-19 is not so spread in Africa: How does Ivermectin affect it? medRxiv. https://doi.org/10.1101/2021.03.26.21254377 Summary: This article explores the low incidence of COVID-19 in Africa, investigating the potential effects of ivermectin, a treatment for onchocerciasis, on morbidity and mortality rates. A statistical analysis was conducted
Reference: Nakagami, H. (2021). Development of COVID-19 vaccines utilizing gene therapy technology. International Immunology, 33(10), 521–527. https://doi.org/10.1093/intimm/dxab013 Summary: The article discusses the urgent development of COVID-19 vaccines in response to the SARS-CoV-2 outbreak. Various vaccine technologies are being explored, categorised into four main groups: intact target viruses, proteins, viral vectors, and nucleic acids. RNA and
Reference: Seneff, S., & Nigh, G. (2021). Worse than the disease? Reviewing some possible unintended consequences of the mRNA vaccines against COVID-19. International Journal of Vaccine Theory, Practice, and Research, 2(1), 38-58. Summary: The article by Seneff and Nigh reviews the mRNA vaccines developed for COVID-19, primarily focusing on the Pfizer and Moderna vaccines. While
Reference: Yagisawa, M., Foster, P. J., Hanaki, H., & Ōmura, S. (2021). Global trends in clinical studies of ivermectin in COVID-19. The Japanese Journal of Antibiotics, 74(1), 44-73. https://doi.org/xxxxxx Summary: The article reviews the global response to the COVID-19 pandemic, particularly the role of ivermectin as a potential treatment. Initially regarded as ineffective, ivermectin gained
Reference: Yagisawa, M., Foster, P. J., Hanaki, H., & Ōmura, S. (2021). Global trends in clinical studies of ivermectin in COVID-19. The Japanese Journal of Antibiotics, 74(1), 44-75. Summary: The article reviews global clinical studies of ivermectin as a potential treatment for COVID-19. Initially, the outbreak was poorly communicated by the Chinese government, leading to
Reference: Centres for Disease Control and Prevention. (2021, March 4). Understanding mRNA COVID-19 vaccines. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html Summary: mRNA vaccines represent a novel approach to immunisation against infectious diseases, including COVID-19. They work by instructing cells to produce a harmless piece of the virus’s spike protein, eliciting an immune response without introducing the live virus. This process
Reference: Bryant, A., Lawrie, T. A., Dowswell, T., Fordham, E., Hill, S., Mitchell, S., & Tham, T. (2021). The BIRD recommendation on the use of ivermectin for Covid-19: Proceedings and conclusions of the British Ivermectin Recommendation Development meeting held on the 20th February 2021 in Bath, United Kingdom. Evidence-Based Consultancy Medicine Ltd. Summary: The British